skip to main content

Will New Injection Devices for Interferon Beta-1a s.c. Affect Treatment Adherence in Patients With Multiple Sclerosis? An Expert Opinion in the Middle East

Deleu, Dirk ; Alsharoqi, Issa ; Jumah, Mohammed Ali Al ; Tahan, Abdel Rahman Al ; Bohlega, Saeed ; Dahdaleh, Maurice ; Inshasi, Jihad ; Khalifa, Ahmad ; Szólics, Miklos ; Yamout, Bassem I

International journal of neuroscience, 2011-03-02, Vol.121 (4), p.171-175 [Periódico revisado por pares]

Informa Healthcare

Texto completo disponível

Citações Citado por
  • Título:
    Will New Injection Devices for Interferon Beta-1a s.c. Affect Treatment Adherence in Patients With Multiple Sclerosis? An Expert Opinion in the Middle East
  • Autor: Deleu, Dirk ; Alsharoqi, Issa ; Jumah, Mohammed Ali Al ; Tahan, Abdel Rahman Al ; Bohlega, Saeed ; Dahdaleh, Maurice ; Inshasi, Jihad ; Khalifa, Ahmad ; Szólics, Miklos ; Yamout, Bassem I
  • Assuntos: Adherence ; disease-modifying drugs ; injection devices ; middle east ; multiple sclerosis
  • É parte de: International journal of neuroscience, 2011-03-02, Vol.121 (4), p.171-175
  • Descrição: ABSTRACT Treatment adherence to disease modifying drugs (DMDs) in multiple sclerosis is sub-optimal. This, in turn, can affect patients' long-term responses to therapy. A key factor that influences treatment adherence is the need for self-injection of DMDs, which can be demanding and disruptive for patients, and difficult for those with cognitive difficulties or reduced manual dexterity. In addition, pain resulting from poor injection technique, and needle anxiety, may both compromise adherence. Changes to the formulation of interferon (IFN) beta-1a for subcutaneous injection that were designed to improve injection local tolerability, and changes in drug-delivery technology, designed to make injections simpler and more convenient for patients, were reviewed by a group of experts on MS in the Middle East. The group also considered the possible effects of these changes in drug delivery technology on patient adherence to IFN beta-1a s.c.
  • Editor: Informa Healthcare
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.